EC5026

• Description:

  EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 shows efficacy for inflammatory and neuropathic pain[1].

• Product Name Alternative:

  BPN-19186

• UNSPSC:

  12352005

• Hazard Statement:

  H301

• Target:

  Epoxide Hydrolase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/ec5026.html

• Purity:

  98.13

• Solubility:

  DMSO : ≥ 250 mg/mL

• Smiles:

  O=C(NC1CCN(C([C@@H](C)CC)=O)CC1)NC2=CC=C(OC(F)(F)F)C(F)=C2

• Molecular Formula:

  C18H23F4N3O3

• Molecular Weight:

  405.39

• Precautions:

  H301

• References & Citations:

  [1]EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain.2019.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [1809885-32-2]